Dorsey Brian 4
4 · ARS Pharmaceuticals, Inc. · Filed Nov 14, 2025
Insider Transaction Report
Form 4
Dorsey Brian
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-13$0.64/sh+21,828$13,970→ 32,617 total - Sale
Common Stock
2025-11-13$8.71/sh−21,828$190,050→ 10,789 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-13−21,828→ 0 totalExercise: $0.64Exp: 2028-11-28→ Common Stock (21,828 underlying)
Footnotes (3)
- [F1]Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025.
- [F2]The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.